Transpharmation Ltd receive prestigious Horizon 2020 Grant

We are delighted to announce that Transpharmation Ltd is to be one of the partners enlisted in the EU-funded first international project to study dystrophin in the brain in Duchenne and Becker Muscular Dystrophy (DMD and BMD).* Intellectual disability and neurobehavioural comorbidities affect at least 50% of the individuals with DMD, which, although a rare genetic disease, is the most common form of muscular dystrophy in childhood. Being the part of the BIND project - an acronym for Brain Involvement in Dystrophinopathies - means that Transpharmation can be directly involved in deep phenotyping of multiple transgenic mice lines (DMD transgenic models) and postnatal restoration of one dystrophin isoform using genetic therapies. https://worldduchenne.org/bind-kickoff/

*This project has received funding by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847826

A personal global service

Transpharmation's CEO, Mark Duxon accompanied by Principal Scientist Dr Sandor Kantor PhD have recently returned from several client visits in Japan. Back at HQ in London we hosted visits from a number of European clients during January. Whether you are a current client or a potential one, we are always happy for you to visit our labs, meet our scientists and gain a more in-depth view of how we work. Whether you'd like to come and see us or you'd like us to visit you, please don't hesitate to get in touch with me. My contact details are below.

Keeping you all updated

If you have a colleague that would benefit from receiving this newsletter please send them a link to our website; subscribing is easy. The website is constantly updated with scientific events that we're attending along with posters that we've presented and details of all the preclinical services that we offer. If you don't see what you need, please do contact us and we'll put our heads together to work out a way forward.

We’re always keen to hear from you

Transpharmation Ltd are a global CRO, wherever you are, whatever language you speak, we’d be happy to work with you. If you have a project in mind for 2020, please contact me, Kerry Waters, Business Development Manager, I look forward to hearing from you.

kerry.waters@transpharmation.co.uk
www.transpharmation.co.uk

Services

You are receiving this newsletter because you have expressed an interest in Transpharmation in the past. If you no longer wish to receive communications such as this from us please unsubscribe here Unsubscribe Thank you.